Prospective, Non-Randomised Clinical Trial to Investigate the BeGraft Aortic Stent Graft System and the BeGraft Peripheral Stent Graft System Treating Aortic-iliac Occlusive Disease

General Inclusion criteria

• Patient has been identified with an chronic aorto-iliac occlusive lesion, with clinical necessity for treatment.
• The patient has been diagnosed with symptomatic peripheral artery disease, defined by Rutherford Becker Classification score 2 to 5.
• Patient has a projected life-expectancy of at least 24 months.
• Patient is ≥18 years old.
• Patient is willing/capable and provides written consent to participate to the trial and confirmed to attend the expected follow-up visits.

Angiographic inclusion criteria:

• Patient's anatomy is eligible for CERAB treatment, without the need for chimneys and can be treated with a Ø 12 mm BGA.
• The aorto-iliac lesion begins at least 1 cm below the patent renal arteries without a need for treatment.
• A maximum of 3 BeGraft Peripheral (Ø 7 or 8 mm) per limb in the iliac artery can be used. In case a Ø 7 mm is used to extend, the overlapping end must be post-dilated to ensure proper flow.
• The target lesion has angiographic evidence of stenosis >50% or occlusion.
• Patient's common femoral artery and deep femoral artery are patent.

General Exclusion criteria:

• Patient is currently participating in another interventional drug trial or device trial that has not completed the entire follow up period.
• Patient has planned any surgical intervention/procedure, that is not related to the study procedure, within 30 days after the study procedure.
• Patient had a Myocardial infarction or stroke within a period of 3 months prior to the study procedure.
• Patient had surgery (e.g. bypass surgery or stenting) in target vessels previously.
• Patient has an acute severe systemic infection at time of screening or in period of 30 days prior to screening.
• Patient has fresh thrombus at time of screening or in period of 14 days prior to screening.
• Patient has a CERAB procedure that is staged.
• Female patient with childbearing potential not taking adequate contraceptives.
• Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated.
• Patients with known hypersensitivity to the stent material (L605) and/or PTFE.
• Patients who are placed in an institution due to an institutional or court order.
• An aneurysm in the abdominal aortic and iliac segments where CERAB will be placed is present.
• Patient has or had aortic coarctation.
• Patient had aortic injury/trauma related interventions previously.
• Patient had suprarenal/visceral segment reconstructions previously.

Angiographic exclusion criteria

• Failure of recanalization
• A relevant accessory renal artery (>3 mm) in the infrarenal aorta is present, that might be occluded during the procedure.